Where AI Actually Works in Biotech
As biotech leaders, you aren’t struggling to find data, you are struggling to make it actionable.
We see it across the industry: clinical trials stall because the right patients can’t be identified in time. Promising drug candidates fail in late stages, burning through years of capital and investment. Genomic datasets are compounding at a rate that vastly outpaces human interpretation. Meanwhile, the market pressure to reduce costs and accelerate life-saving outcomes has never been higher.
The biopharma industry doesn’t lack innovation; it lacks the underlying systems required to translate immense complexity into confident, real-time decisions.
Artificial intelligence is often presented as the solution. Yet, on the ground, its impact remains uneven. We see some initiatives delivering measurable ROI, while others remain stuck in pilot stages. The distinguishing factor is not the sophistication of the AI model. It is where and how that AI is applied.
At Sigma Software, we partner with biotech and healthcare organizations that have moved past the hype. They need systems that operate in real-world environments, integrate with existing infrastructure, and support mission-critical decisions.
Based on validated data, real use cases, and our implementation experience, this article explains where AI is already delivering value in biotech.
The Shift From Experimentation to Practical Use
Over the past decade, biotech companies have invested heavily in AI. However, many early initiatives were exploratory.
That phase is ending.
According to McKinsey, AI could generate $60 billion to $110 billion annually for pharmaceutical and medical-product companies. At the same time, the cost of developing a single drug can reach $1–2.8 billion
These numbers explain why companies are no longer asking if they should adopt AI. They are asking where it delivers results.
Biotech Domain | Core AI Application | Validated Industry Impact |
Clinical Trials | Automated EHR scanning, predictive trial design | 35–45% productivity improvement; Phase III timelines reduced by ~30% |
Genomics | Variant identification, biomarker discovery | Enables scalable precision medicine |
Drug Discovery | Target identification, predictive toxicity | Early-stage timelines reduced by up to 1/3 |
Operations | Regulatory automation, supply chain optimization | $4–7 billion annual value (McKinsey) |
Clinical Trials: Where Small Improvements Create Large Impact
A biotech company can spend years preparing a clinical trial, only to face delays because patient recruitment takes longer than expected. This is one of the most common and costly bottlenecks. AI is already changing this.
Instead of manually reviewing patient records, AI systems can scan electronic health records and identify eligible participants in a fraction of the time. This directly reduces delays and improves enrollment quality.
Beyond recruitment, AI is also being used to improve trial design. By analyzing historical data, it can identify unrealistic inclusion criteria or predict risks before a trial begins.
The impact becomes even clearer during execution. According to industry analysis, AI can improve productivity in clinical development by 35–45%
In some cases, Phase III timelines have been reduced by around 30%. These are not marginal gains. They directly affect time to market and overall R&D cost. However, these results depend on more than algorithms. They require systems that integrate with EHRs, unify fragmented data, and operate within strict regulatory frameworks.
This is where many initiatives fail, and where custom software becomes essential.
Genomics: When Data Volume Exceeds Human Capacity
Genomics presents a different challenge. Here, the issue is not inefficiency. It is a scale. A single genome contains billions of data points. Interpreting this data manually is not realistic, especially when combined with clinical and population-level datasets. AI changes what is possible.
It can identify which genetic variants are clinically relevant, group patients based on genetic profiles, and detect patterns that lead to new biomarkers.
This is already influencing how therapies are developed. Instead of targeting broad populations, companies can design treatments for specific patient groups. As a result, precision medicine is becoming more practical, not just theoretical. However, genomics also highlights a critical requirement: infrastructure.
AI models need access to high-performance computing, secure data environments, and integration with sequencing platforms. Without this foundation, even accurate models cannot be used in clinical workflows.
For many organizations, the challenge is not building the model. It is building the system around it.
Drug Discovery: Improving Early Decisions, Not Replacing Science
Drug discovery is often where AI attracts the most attention.
The promise is clear. Reduce the time needed to identify viable drug candidates and avoid costly failures later.
In practice, AI is delivering value, but in a specific way. It helps researchers make better early decisions.
AI models can analyze biological data to identify promising targets. They can generate candidate molecules and predict potential toxicity before laboratory testing begins.
This reduces the number of weak candidates entering the pipeline. According to McKinsey, AI can reduce early-stage timelines by up to one-third Real-world examples show even stronger results. Some AI-driven programs have moved drug candidates into clinical trials in 18 months, compared to an average of 42 months . However, it is important to be precise. AI does not replace laboratory validation or clinical trials. It improves the quality of decisions before those stages begin.
This distinction is critical for setting realistic expectations and planning investments.
Real-World Data: Understanding What Happens After Approval
Once a drug reaches the market, the focus shifts from development to performance.
This is where real-world data becomes essential.
AI can analyze large datasets from clinical records, insurance claims, and wearable devices to understand how treatments perform outside controlled trial environments.
This supports pharmacovigilance, improves treatment protocols, and provides evidence for regulators and payers. As regulatory expectations evolve, the ability to generate real-world evidence is becoming a requirement, not an advantage.
Explore Sigma Software’s Medical AI Assistance Solutions for Healthcare Services
Operational Efficiency: The Overlooked Opportunity
While most discussions focus on R&D, many biotech companies see faster returns from operational improvements. AI is already being used to automate documentation, streamline regulatory submissions, and optimize supply chains.
According to McKinsey, generative AI could unlock $4–7 billion annually in value across biopharma operations These use cases may not be as visible as drug discovery, but they often deliver faster and more predictable ROI.
Why Many AI Initiatives Still Fail
Despite clear opportunities, many AI projects in biotech do not reach production.
Common reasons why AI initiatives fail:
- Fragmented data across systems
- Lack of integration planning
- Late consideration of regulatory requirements
- Poor performance in real-world conditions
There is also a gap between technical performance and real-world reliability. Research shows that many models perform well in controlled environments but fail to generalize in practice.
These challenges are not purely technical. They are architectural.
How Sigma Software Approaches AI in Biotech
At Sigma Software, we focus on making AI work in real environments.
This starts with understanding the problem, not selecting the technology.
Our approach includes:
- Data pipelines first: We unify fragmented data into structured, usable systems.
- Integration by design: We connect AI solutions with EHRs, laboratory systems, and research platforms.
- Compliance from the start: We build systems aligned with healthcare regulations from day one.
- Scalable architecture: We create solutions that grow with your data and use cases.
This approach allows our clients to move beyond pilot projects and deploy AI where it supports actual decision-making.
What Biotech Leaders Should Focus On Next
The companies that succeed with AI are not those that experiment the most. They are the ones that focus on the right problems.
This means:
- Prioritizing data infrastructure before advanced models
- Focusing on high-impact areas such as clinical trials and genomics
- Ensuring systems are explainable and compliant
- Working with partners who understand both technology and healthcare
Navigating the Practical Reality of AI in Biotech
AI delivers its strongest ROI in biotech when applied to data-heavy domains like clinical trial optimization, genomic data analysis, and drug discovery. These areas allow machine learning to solve specific problems where traditional methods often fail.
Focus on Systems, Not Just Models
The primary hurdle for biotech today is not a lack of models but a lack of infrastructure. For AI to be effective, it must be supported by systems that ensure data integrity, meet regulatory standards, and scale across an organization.
- Prioritize Integration: Move beyond isolated pilots and embed AI into active R&D workflows.
- Focus on Utility: Build the underlying architecture that makes results consistent and reliable.
At Sigma Software, we specialize in this transition. We help organizations design AI solutions that function as core components of clinical and research processes.
Strategic Next Steps
To see results, focus on proven use cases and invest in the technical foundation required to make AI usable in practice. Success lies in the “last mile” of implementation where software meets science.
How are you currently balancing the need for new AI models with the practical challenge of integrating them into your existing research workflows?
Want to see what this looks like in practice? Let’s talk.
Let’s talk about your unique workflows and design a custom digital health solution that supports outcome-based care, improves population health, and aligns with value-based reimbursement models.
Whether you’re navigating HEDIS metrics, improving care coordination, or optimizing performance-based contracts, we can help.
Build Your Custom Implementation Plan
Your implementation plan includes integrations, MVP timelines, and long-term support strategies. We build your value-based care solution around real workflows, compliance requirements, and measurable outcome goals.
Launch and Optimize for Outcome-Based Development
Our solutions combine predictive analytics, AI-driven clinical insights, and secure, interoperable data flows. Whether you need compliance tools, shared savings tracking, or a care coordination engine, we align it with your quality metrics, reimbursement goals, and care delivery model.
Ready to Improve Outcomes with Custom Value-Based Solutions?
We design and build custom software for value-based healthcare, built around your data, workflows, and objectives. Whether you need to unify data, support attribution, or track performance across contracts—we’re here to build what works.
Biotech companies can implement AI successfully by starting with a high-impact use case, such as clinical trial optimization or genomic analysis.
They should then:
- Build a strong data infrastructure
- Ensure system integration and interoperability
- Address regulatory compliance early
- Work with experienced partners in healthcare software development
A structured approach enables the transition from pilot projects to scalable, production-ready AI systems.
Custom software is critical because AI solutions must integrate with existing biotech systems, including EHRs, лаборатory platforms, and research databases.
Off-the-shelf tools often cannot meet requirements for integration, compliance, and scalability. Custom development ensures that AI solutions are usable in real clinical and R&D environments.
The most common challenges include:
- Fragmented data across multiple systems
- Complex regulatory and compliance requirements
- Difficulty integrating AI into existing clinical and R&D workflows
In practice, many AI initiatives fail not because of the model itself, but because the surrounding systems are not designed for production use.
AI improves clinical trials by accelerating patient recruitment, optimizing protocols, and supporting real-time patient monitoring. For example, AI systems can process electronic health records to identify eligible patients faster and detect risks in trial design before execution.
Industry data shows AI can increase clinical development productivity by up to 35–45%. In practice, achieving these results requires integration with EHR systems, reliable data pipelines, and compliance with healthcare regulations.
CMS LEAD Model Explained: Strategy, Risk & Readiness Checklist
RPM Impact Report: Reducing Nurse Burden & Attrition
The Clinical Impact Report: Precision Remote Patient Monitoring
Virtual Nursing Software Development: Building High-Availability Patient Monitoring for 2026
Checklist for Healthcare Organizations in 2026: Preparing for Value-Based Care
Care Coordination Software: Key to Unlocking Value-Based Care for Providers and Payers
Stay in the loop with everything you need to know.